People · Operator
Named in public records as an officer, director or promoter · active 2017–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $29.0M | $239.2M | 2017 |
Patrick Lin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Patrick Lin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Young | 1 | 16 |
| Justin Yorke | 1 | 5 |
| Virgil Thompson | 1 | 4 |
| Reginald Greenslade | 1 | 2 |
| Larry Griffin | 1 | 2 |
| Gus Blass, III | 1 | 2 |
| David Dworsky | 1 | 1 |
| Alex Kramer | 1 | 1 |
| Helen W. Pentikis | 1 | 1 |
| Richard Giles | 1 | 1 |
| Hugh Wolff | 1 | 1 |
| Justin York | 1 | 1 |
| Allen Dodge | 1 | 1 |
| Justin W. Yorke | 1 | 1 |
| Virgil W. Thompson | 1 | 1 |
| Michael W. Floyd | 1 | 1 |
| Wendy W. Guy | 1 | 1 |
| Khalid W. Islam | 1 | 1 |
| Geraldine W. Pannu | 1 | 1 |
| James W. Stanker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.